August 1, 2011
A critical eye on Infuse use studies
A leading spine journal is casting a critical eye on industry-supported research that has led to widespread use of Medtronic's controversial bone growth product Infuse. The June 2011 issue of Spine Journal carries a strongly worded editorial about the trial designs, reporting bias, and peer review shortfalls that the authors say have promoted the product's widespread use, with "eventual life-threatening complications and deaths."
Free Daily News
- Novel liver transplant technique offers new hope for colorectal cancer patients
- Bipartisan bill would expand presidential trade authority over medical goods
- Legislation proposes granting CRNA practice authority to expand anesthesia access for veterans
- FDA announces Class 1 recall for implantable ports
- FDA designates Class 1 recall for embolization devices
- AI reshapes healthcare leadership
- The Joint Commission launches UNIFY 2025 to advance patient safety, healthcare quality
- Insights into spinal vs general anesthesia: Which comes out on top for same-day outpatient surgery?
- US News & World Report releases results of second annual ‘Best ASCs’ ratings
- Hospitals make steady gains in patient safety amid persistent challenges
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement